William Blair

Tesla Inc. (NASDAQ:TSLA) CEO Elon Musk has spoken out about the “Big Beautiful Bill” backed by President Donald Trump and Congress on several occasions. The bill will make it more expensive for consumers to buy electric vehicles and provide less credits for EV companies. One analyst...

Nektar Therapeutics (NASDAQ:NKTR) released on Tuesday statistically significant data from the 16-week induction period of the ongoing Phase 2b REZOLVE-AD study of investigational rezpegaldesleukin. The trial met its primary endpoint of the mean improvement in Eczema Area and Severity Score (EASI)...

Viking Therapeutics, Inc. (NASDAQ:VKTX) on Wednesday initiated the VANQUISH Phase 3 clinical program for VK2735, the company’s dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2375 is being developed in oral and...

Earlier this week, Sarepta Therapeutics, Inc (NASDAQ:SRPT) provided a safety update regarding Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy for patients with Duchenne muscular dystrophy, and steps the company is taking to strengthen the safety profile in non-...

Quest Diagnostics Inc (NYSE:DGX) reported on Tuesday that first-quarter 2025 sales of $2.65 billion, up 12.1% year over year, beat the consensus of $2.63 billion. The diagnostic test provider reported quarterly adjusted earnings of $2.21 per share, up 8.3%, beating the consensus of $2.15....

Altimmune Inc (NASDAQ:ALT) hosted a virtual R&D day on Thursday, marking the first disclosure of Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD) as potential developments for pemvidutide. Phase 2 trials for pemvidutide in AUD and ALD are expected to start in the second and third...

Pyxis Oncology, Inc. (NASDAQ:PYXS) announced on Thursday, a portfolio prioritization, focusing resources on advancing its lead clinical program, PYX-201. Pyxis Oncology’s second clinical program, PYX-106, is being deprioritized to allocate resources toward advancing the lead asset, PYX-201....

Repligen Corp (NASDAQ:RGEN) released on Tuesday third-quarter adjusted EPS of 43 cents, up from 23 cents a year ago, beating the consensus of 33 cents. The bioprocessing technology reported sales of $154.87 million, up 10% year-over-year, beating the consensus of $153.23 million. Olivier Loeillot,...

Editor's Note: The article has been corrected to note that this was Intuit's second-quarter earnings report. Intuit Inc (NASDAQ: INTU) reported in-line revenues but managed an earnings beat in the second quarter. The results came amid an exciting earnings season. Here are some key...

Shares of Carvana Co (NYSE: CVNA) were climbing in early trading on Friday, after the company reported its fourth-quarter results. The results came amid an exciting earnings season. Here are some key analyst takeaways from the release. RBC Capital Markets On Carvana Analyst Brad Erickson maintained...

Block Inc (NYSE: SQ) Thursday reported its fourth-quarter results and issued full-year guidance. The results came amid an exciting earnings season. Here are some key analyst takeaways from the release. Keefe, Bruyette & Woods analyst Vasundhara Govil maintained a Market Perform rating, while...

Twilio Inc (NYSE: TWLO) shares tanked in early trading on Thursday, even after the company reported upbeat results for its fourth quarter. The results, which included Twilio not releasing a full-year outlook, saying it would provide the forecast in March, were announced amid an...

Shares of Uber Technologies Inc (NYSE: UBER) rose sharply on Wednesday, after the company announced the share repurchase of up to $7 billion. Last week, the ride-sharing giant announced its fourth-quarter results amid an exciting earnings season. Here are some key analyst takeaways from the company...

Shares of Chegg Inc (NYSE: CHGG) slipped in early trading on Tuesday, after declining more than 8% in the premarket session. The company reported its fourth-quarter results amid an exciting earnings season. Here are some key analyst takeaways from the release. Piper Sandler analyst Arvind Ramnani...

Shares of Palantir Technologies Inc (NYSE: PLTR) were climbing Tuesday after the company reported better-than-expected fourth-quarter results. Here's what four analysts are saying about the earnings report.  Wedbush On Palantir Technologies Analyst Daniel Ives maintained an...